Personalised Immuno NEOGAP Therapeutics AB is a private, clinical-stage biotech focusing on personalised immunotherapies for solid tumors, indicating a potential fit for partnerships with CROs, CDMOs, and diagnostic collaborators to co-develop cell-based treatments and scalable manufacturing.

Financing Momentum Recent financing round of SEK 87 million led by Sciety plus ongoing grants from Vinnova suggests strong investor and grant support, signaling budget availability for collaboration, joint development projects, and potential co-investment opportunities in trials or manufacturing scale-up.

CollaborativePathways Strategic collaboration with NorthX Biologics for manufacturing strategies demonstrates openness to external manufacturing partnerships; this could translate into discussions for extended manufacturing services, GMP process development, and supply chain co-ownership for cell therapies.

Academic Ties Close ties to Karolinska Institute and partnerships with Weill Cornell Medicine indicate access to top-tier clinical and translational science networks, offering avenues for clinical trial collaboration, access to patient cohorts, and joint grant applications.

ClinicalStageNote pTTL, a personalised cell-based immunotherapy in Phase I/II for advanced colorectal cancer, presents a near-term opportunity to engage in companion diagnostics, biomarker development, and early-access programs with hospitals and payers as the program progresses.